Ansa Biotechnologies has unveiled its 50 kilobase (kb) Clonal DNA product, marking a significant advancement in DNA synthesis. This new offering is the longest sequence-perfect synthetic DNA commercially available and is made possible through the company's proprietary enzymatic synthesis platform. With the Ansa On-Time Guarantee, customers can expect to receive complete, error-free DNA constructs in less than 25 days, a breakthrough that addresses long-standing challenges in gene synthesis.

“Ansa has provided us with extremely long and complex constructs we couldn't get anywhere else,” said Molly Gasperini, PhD, Associate Director of Genome Engineering at the Allen Institute’s Seattle Hub for Synthetic Biology. Traditional chemical DNA synthesis methods typically struggle to produce sequences longer than 10 kb, often leading researchers to manually assemble smaller fragments, which can introduce errors and delays. Ansa’s innovative platform overcomes these limitations by enabling the direct synthesis of long, complex sequences with unparalleled precision and sustainability. Each construct undergoes extensive verification through long-read sequencing and proprietary informatics quality control, ensuring accuracy. The Ansa On-Time Guarantee provides assurance that customers will receive their complete orders on time, or they will get their DNA for free.

“For these types of sequences, as long as 50 kb, other providers often reject or quote an extremely long ETA,” Gasperini added. “Without Ansa, we couldn't obtain them so efficiently, affordably, and reliably — or at all!”

The launch of Ansa's new product follows a successful early access program that included more than 20 leading institutions. Participants utilized Ansa’s long synthetic DNA to break through traditional synthesis barriers, facilitating advancements in synthetic genomics, metabolic engineering, agriculture, and the development of cell and gene therapies. The ultra-long, fully sequence-verified DNA constructs are now available globally for as low as 28 cents per base pair, with turnaround times under 25 business days. Ansa's pricing strategy is transparent, with costs decreasing as sequence lengths increase.

“We are very excited about the Ansa technology, which has derisked timelines for creating our TARGATT™ donor plasmids," said Dolores Baksh, PhD, CEO of Applied StemCell. "Ansa's large DNA synthesis capabilities align well with the strength of our TARGATT™ technology, which efficiently and site-specifically inserts multi-protein constructs into the H11 safe harbor site in mammalian cells. We find that Ansa can even do difficult and complex sequences that can be challenging to clone or synthesize, and the inserted DNA always expresses well.”

“For years, scientists have been limited by what they could build, not what they could imagine,” stated Jason T. Gammack, Chief Executive Officer of Ansa Biotechnologies. “By delivering 50 kb sequence-perfect DNA in weeks, and guaranteeing it on time, we’re unlocking the next era of biological design, where imagination, not manufacturing, sets the limits.”

The launch of the 50 kb product is part of Ansa’s ongoing expansion, bolstered by a recent $54.5 million Series B financing round. The company's mission is to accelerate discovery through next-generation DNA synthesis. Exclusively produced in the United States, Ansa's DNA products integrate seamlessly into existing research workflows, aiming to empower the next generation of biological discoveries. The company adheres to stringent biosecurity protocols and complies with all requirements set forth by the U.S. Office of Science and Technology Policy Framework for Nucleic Acid Synthesis Screening. For further details about Ansa’s offerings, visit www.ansabio.com/products.